During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Benzinga readers can review the latest analyst takes on their favorite stocks by visiting Analyst Stock Ratings page. Traders can sort through Benzinga’s extensive database of analyst ratings, including by analyst accuracy.

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector.

Viatris Inc (NASDAQ:VTRS)

  • Dividend Yield: 2.94%
  • Barclays analyst Glen Santangelo maintained an Overweight rating and raised the price target from $17 to $22 on May 19, 2026. This analyst has an accuracy rate of 54%.
  • JP Morgan analyst Chris Scott maintained a Neutral rating and increased the price target from $17 to $18 on May 8, 2026. This analyst has an accuracy rate of 64%
  • Recent News: On May 18, the U.S. FDA accepted the company’s new drug application for fast-acting meloxicam for the treatment of moderate-to-severe acute pain.
  • Benzinga Pro’s real-time newsfeed alerted to latest VTRS news.

Medtronic PLC (NYSE:MDT)

  • Dividend Yield: 3.56%
  • Needham analyst Mike Matson maintained a Buy rating with a price target of $101 on June 17, 2026. This analyst has an accuracy rate of 57%.
  • UBS analyst Priya Sachdeva maintained a Neutral rating and cut the price target from $90 to $85 on June 4, 2026. This analyst has an accuracy rate of 72%.
  • Recent News: On June 12, Medtronic announced it has completed its acquisition of Scientia Vascular.
  • Benzinga Pro’s real-time newsfeed alerted to latest MDT news

GSK plc (NYSE:GSK)

  • Dividend Yield: 3.43%
  • Barclays analyst James Gordon downgraded the stock from Equal-Weight to Underweight on Jan. 6, 2026. This analyst has an accuracy rate of 67%
  • Jefferies analyst Michael Leuchten upgraded the stock from Hold to Buy on Oct. 27, 2025. This analyst has an accuracy rate of 63%.
  • Recent News: On June 24, GSK commenced tender offer to acquire Nuvalent at $124 per share.
  • Benzinga Pro’s real-time newsfeed alerted to latest GSK news

Photo via Shutterstock